Ramipril

International Journal of Clinical Practice

Volumn 54, Issue 4, 2000, Pages 255-260

  Smith, W H T ^a   Ball, S G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; RAMIPRIL; SPIRONOLACTONE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PROTEINURIA; RAMIPRIL;

EID: 0034105175     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circulation Res 1993; 72(6): 1202-1210.
2. Martorana PA, Scholkens BA. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors. Agents Actions 1992; 38(suppl Pt 3): 98-102.
3. Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20(suppl 9): S83-S90.
4. Todd PA, Benfield P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39(1): 110-135.
5. Ball SG, Robertson JI. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59(10): 23D-27D.
6. Eckert HG, Badian MJ, Gantz D et al. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittel-Forschung 1984; 34(10B): 1435-1447.
7. Bender N, Rangoonwala B, Rosenthal J, Vasmant D. Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications. Clin Physiol Biochem 1990; 8(suppl 1): 44-52.
8. McCarron D. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group. Clin Cardiol 1991; 14(9): 737-742.
9. Spieker C, Zidek W, Vetter H, Rahn KH. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril. J Int Med Res 1991; 19(1): 39-43.
10. Heber ME, Brigden GS, Caruana MP et al. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril. Am J Cardiol 1988; 62(4): 239-245.
11. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Therapeut 1996; 18(4): 658-670.
12. Kaneko Y, Omae T, Yoshinaga K et al. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension. Am J Cardiol 1987; 59(10): 86D-91D.
13. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
14. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83(6): 1849-1865.
15. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26(7): 809-820.
16. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83(5): 1771-1779.
17. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension: results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13(11): 1325-1334.
18. Eichstaedt H, Danne O, Langer M et al. Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging. J Cardiovasc Pharmacol 1989; 13(suppl 3): S75-S80.
19. The CONSENSUS Trial Study Group. Effects of en alapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-1435.
20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
21. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325(5): 303-310.
22. Beermann B, Nyquist O, Hoglund C et al. Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure: a placebo controlled three-dose study. Eur J Clin Pharmacol 1993; 45(3): 241-246.
23. Lubsen J. ACE inhibitors in the treatment of heart failure: special emphasis on ramipril. Rev Contemp Pharmacother 1996; 7: 15-22.
24. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-717.
25. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349-1355.
26. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
27. MERIT HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP). Lancet 1999; 353: 2001-2007.
28. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-888.
29. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493-7.
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20): 1456-1462.
31. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
32. Ruggencnti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-1256.
33. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
34. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events, in high-risk patients. N Engl J Med 2000; 342: 145-153.
35. Pitt B, Poole-Wilson PA, Segal R et al. Losartan Heart Failure Survival Study-Elite II. Circulation 1999; 100(18): 1782-1782.